As a summary, our study first indicated that targeting c-MET therapies improved PFS and DCR but not OS and ORR in advanced or metastatic NSCLC patients, especially in previous treated Asian patients with adenocarcinoma. The gene discussed is MET; the disease is non-small cell lung carcinoma.